drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Patient-derived T cells genetically modified to express an HLA-A–restricted T-cell receptor recognizing mutant KRAS G12V/G12D neoantigens; administered as adoptive cellular therapy to mediate MHC-restricted cytotoxic tumor killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an HLA-A–restricted T-cell receptor specific for mutant KRAS G12V/G12D peptides. After infusion, these TCR-T cells recognize KRAS neoantigens presented on tumor MHC, become activated, and mediate MHC-restricted cytotoxic killing via perforin/granzyme release and cytokine secretion, leading to selective elimination of KRAS-mutant tumor cells.
drug_name
Autologous KRAS G12V/G12D-specific TCR-engineered T cells
nct_id_drug_ref
NCT05438667